Treatment Information

Back

Melanoma treatment details. Biologic therapy, Immunotherapy.

The Ohio State University, Columbus, OH, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Columbus, OH
Treatments:Biologic therapy, ImmunotherapyHospital:The Ohio State University
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This phase 2 study involved 25 metastatic melanoma patients. The median patient age was 56 years and 16 were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and the immunotherapy agent interferon alpha-2B (IFN-alpha) which stimulates the immune system to fight the cancer.

Toxicities:
There was one reported adverse event-related death due to stroke. Grade 3-4 blood clots, joint pain, and neutropenia were also reported.

Results:
The median overall survival was 17 months.

Support:
Some of the researchers have consulted for or received funding from Genentech.

Correspondence: Dr. William E. Carson; email: [email protected]



Back